3-Nitropropionic acid toxicity in hippocampus: Protection throughN-methyl-D-aspartate receptor antagonism
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The over-activation of glutamate receptors can lead to excitotoxic cell death and is believed to be involved in the progression of neurodegenerative events in the vulnerable hippocampus. Here, we used an in vitro slice model to study toxicity produced in the hippocampus by the mitochondrial toxin 3-nitropropionic acid (3-NP). The organotypic slice cultures exhibit native cellular organization as well as dense arborization of neuronal processes and synaptic contacts. The hippocampal slices were exposed to 3-NP for 2-20 days, causing calpain-mediated breakdown of the spectrin cytoskeleton, a loss of pre- and postsynaptic markers, and neuronal atrophy. The N-methyl-D-aspartate (NMDA) receptor antagonist memantine reduced both the cytoskeletal damage and synaptic decline in a dose-dependent manner. 3-NP-induced cytotoxicity, as determined by the release of lactate dehydrogenase, was also reduced by memantine with EC50 values from 1.7 to 2.3 microM. Propidium iodide fluorescence and phase contrast microscopy confirmed memantine neuroprotection against the chronic toxin exposure. In addition, the protected tissue exhibited normal neuronal morphology in the major hippocampal subfields. These results indicate that antagonists of NMDA-type glutamate receptors are protective during the toxic outcome associated with mitochondrial dysfunction. They also provide further evidence of memantine's therapeutic potential against neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · cited 1×
“…of excitotoxic processes including ischemia, traumatic brain injury, and oxidative stress (see Kemp and MeKernan, 2002; Waxman and Lynch, 2005; Lipton, 2006), and perhaps contributes to Alzheimer's disease (AD) and other age-related disorders (Ulas et al., 1994; Hynd et al., 2004; Mishizen-…”
BackgroundCalcium in Ischemic Cell Death
Kristián, T., & Siesjö, B. K. (1998) · Stroke · doi:10.1161/01.str.29.3.705 · Cited by 825 · cited 2×
“Other factors to consider are potential mitochondrial release factors that promote secondary events that directly modulate NMDA receptors (Manzoni et al., 1992; Kristian and Siesjo, 1998; Choi et al., 2000).”
BackgroundMartin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684 · cited 1×
“The toxic action of 3-NP is of particular interest since mitochondrial dysfunction may contribute to both excitotoxic progression and age-related neurodegenerative disorders (see Beal et al., 1993; Miller and Zaborszky, 1997; Martin et al., 2006).”
BackgroundMiniature synaptic events maintain dendritic spines via AMPA receptor activation
McKinney, R. A., Capogna, M., Dürr, R., Gähwiler, B. H., & Thompson, A. S. M. (1999) · Nature Neuroscience · doi:10.1038/4548 · Cited by 523
Boya, P., Gonzalez-Polo, R.-A., Poncet, D., Andreau, K., Vieira, H. L., Roumier, T., Perfettini, J.-L., & Kroemer, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206622 · Cited by 385 · cited 2×
“Excitotoxicity and free radical generation can enhance the risk of neurodegenerative events, and oxidative damage is thought to be a major factor in age-related diseases, involving mitochondrial membrane permeability, lysosomal dysfunction, and protein accumulation (see Bahr and Bendiske, 2002; Boya et al., 2003; Zhu…”
BackgroundN-Methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease
Waxman, E. A., & Lynch, D. R. (2005) · The Neuroscientist · doi:10.1177/1073858404269012 · Cited by 372 · cited 1×
“…for its role in a variety of excitotoxic processes including ischemia, traumatic brain injury, and oxidative stress (see Kemp and MeKernan, 2002; Waxman and Lynch, 2005; Lipton, 2006), and perhaps contributes to Alzheimer's disease (AD) and other age-related disorders (Ulas et al., 1994; Hynd…”
BackgroundMishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156
Bahr, B. A. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490420303 · Cited by 155
Self-citationMemantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Molinuevo, J. L., Lladó, A., & Rami, L. (2005) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750502000206 · Cited by 125 · cited 1×
“The ability of NMDA antagonists to treat AD may be related to the prevention of the noted apoptotic episodes and vicious cycles (Danysz and Parsons, 2002; Butterfield and Pocernich, 2003; Molinuevo et al., 2005; Sonkusare et al., 2005).”
Background
Cited by
Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Self-citationThe role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Rammes, G., Hasenjäger, A., Sroka-Saidi, K., Deussing, J. M., & Parsons, C. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.051 · Cited by 163
Self-citationRéus, G. Z., Stringari, R. B., Rezin, G. T., Fraga, D. B., Daufenbach, J. F., Scaini, G., Benedet, J., Rochi, N., Streck, E. L., & Quevedo, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-011-0718-2 · Cited by 23
Metadata
- Authors
- Karanian, D. A., Baude, A. S., Brown, Q. B., Parsons, C. G., & Bahr, B. A.
- Venue
- Hippocampus
- Publisher
- Wiley
- Published
- 2006
- Volume
- 16
- Issue
- 10
- Pages
- 834-842
- ISSN
- 1050-9631 (ISSN-L)
- 1098-1063
- OpenAlex
- W2103477251
- Cited by
- 38
- References
- 10
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.